As of 2025-04-29, the EV/EBITDA ratio of Foghorn Therapeutics Inc. (FHTX) is -2.03. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FHTX's latest enterprise value is 188.67 mil USD. FHTX's TTM EBITDA according to its financial statements is -93.00 mil USD. Dividing these 2 quantities gives us the above FHTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.7x - 12.0x | 10.9x |
| Forward P/E multiples | 15.9x - 32.3x | 20.0x |
| Fair Price | (25.56) - (19.11) | (24.84) |
| Upside | -682.2% - -535.2% | -665.9% |
| Date | EV/EBITDA |
| 2025-04-25 | -2.01 |
| 2025-04-24 | -2.08 |
| 2025-04-23 | -2.20 |
| 2025-04-22 | -1.94 |
| 2025-04-21 | -1.74 |
| 2025-04-17 | -1.68 |
| 2025-04-16 | -1.48 |
| 2025-04-15 | -1.54 |
| 2025-04-14 | -1.55 |
| 2025-04-11 | -1.47 |
| 2025-04-10 | -1.34 |
| 2025-04-09 | -1.52 |
| 2025-04-08 | -1.32 |
| 2025-04-07 | -1.60 |
| 2025-04-04 | -1.46 |
| 2025-04-03 | -1.29 |
| 2025-04-02 | -1.45 |
| 2025-04-01 | -1.41 |
| 2025-03-31 | -1.57 |
| 2025-03-28 | -1.51 |
| 2025-03-27 | -1.72 |
| 2025-03-26 | -1.68 |
| 2025-03-25 | -1.78 |
| 2025-03-24 | -1.92 |
| 2025-03-21 | -1.87 |
| 2025-03-20 | -1.89 |
| 2025-03-19 | -2.04 |
| 2025-03-18 | -2.09 |
| 2025-03-17 | -2.16 |
| 2025-03-14 | -2.05 |
| 2025-03-13 | -2.11 |
| 2025-03-12 | -2.17 |
| 2025-03-11 | -2.03 |
| 2025-03-10 | -2.04 |
| 2025-03-07 | -2.11 |
| 2025-03-06 | -2.09 |
| 2025-03-05 | -2.17 |
| 2025-03-04 | -1.97 |
| 2025-03-03 | -1.99 |
| 2025-02-28 | -2.26 |
| 2025-02-27 | -2.28 |
| 2025-02-26 | -2.39 |
| 2025-02-25 | -2.48 |
| 2025-02-24 | -2.49 |
| 2025-02-21 | -2.54 |
| 2025-02-20 | -2.72 |
| 2025-02-19 | -2.91 |
| 2025-02-18 | -2.93 |
| 2025-02-14 | -3.08 |
| 2025-02-13 | -3.12 |